Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) had its price target lowered by stock analysts at Wedbush from $10.00 to $8.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Wedbush‘s price objective suggests a potential upside of 100.50% from the company’s current price.
ACRS has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, September 21st. Wall Street Zen upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. Finally, Canaccord Genuity Group started coverage on Aclaris Therapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $10.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Aclaris Therapeutics has a consensus rating of “Buy” and a consensus target price of $11.00.
View Our Latest Analysis on Aclaris Therapeutics
Aclaris Therapeutics Trading Up 0.8%
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%. The company had revenue of $1.63 million for the quarter, compared to the consensus estimate of $1.38 million. On average, analysts forecast that Aclaris Therapeutics will post -0.62 earnings per share for the current year.
Institutional Investors Weigh In On Aclaris Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Aclaris Therapeutics during the third quarter valued at about $40,000. MBE Wealth Management LLC bought a new position in shares of Aclaris Therapeutics during the 3rd quarter worth about $53,000. Jefferies Financial Group Inc. acquired a new stake in shares of Aclaris Therapeutics in the 2nd quarter valued at about $58,000. Strs Ohio acquired a new stake in shares of Aclaris Therapeutics in the 1st quarter valued at about $60,000. Finally, Legal & General Group Plc acquired a new stake in shares of Aclaris Therapeutics in the 2nd quarter valued at about $61,000. 98.34% of the stock is owned by institutional investors.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.
Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.
See Also
- Five stocks we like better than Aclaris Therapeutics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
